logo
AI Icon𝛼SK or Search
ENTITY

Obsidian Therapeutics (OBX US)

2
Analysis
Health Care • United States
Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors, utilizing its proprietary cytoDRiVE™ platform. Its lead product candidate, amsoki-cel, is currently in Phase 2 clinical trials for advanced melanoma and Phase 1 for non-small cell lung cancer, having demonstrated a 67% objective response rate in melanoma patients during a Phase 1/2 trial.
more
bullish•Obsidian Therapeutics
•31 Aug 2026 22:01

Obsidian Therapeutics (OBX US): Synthetic Expert Call Transcript (31 Aug 2026)

Obsidian Therapeutics’ lead candidate, amsoki-cel (OBX-115), is clinically differentiated by its complete elimination of systemic high-dose...

Logo
Share
bullish•Obsidian Therapeutics
•30 Aug 2026 10:04

IPO Databook: Obsidian Therapeutics (OBX US) - Aug 2026

Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered TIL cell therapies for solid tumors using its...

Logo
Share
No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x